Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy.

Details

Serval ID
serval:BIB_36273
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy.
Journal
Journal of Infectious Diseases
Author(s)
Rockstroh J.K., Mocroft A., Soriano V., Tural C., Losso M.H., Horban A., Kirk O., Phillips A., Ledergerber B., Lundgren J.
ISSN
0022-1899
Publication state
Published
Issued date
2005
Volume
192
Number
6
Pages
992-1002
Language
english
Notes
11th Conference on Retroviruses and Opportunistic Infections San Francisco, California, Febrary 08-11, 2004
Abstract
OBJECTIVE: To assess hepatitis C virus (HCV) antibody prevalence in the EuroSIDA cohort, along with survival, human immunodeficiency virus (HIV)-1 disease progression, virologic response (plasma HIV-1 RNA load of < 500 copies/mL), and CD4 cell count recovery by HCV serostatus in patients initiating highly active antiretroviral therapy (HAART). RESULTS: HCV serostatus at or before enrollment was available for 5957 patients; 1960 (33%) and 3997 (67%) were HCV seropositive and seronegative, respectively. No association between an increased incidence of acquired immunodeficiency syndrome-defining illnesses or death and HCV serostatus was seen after adjustment for other prognostic risk factors known at baseline (adjusted incidence rate ratio [IRR], 0.97 [95% confidence interval {CI}, 0.81-1.16]). However, there was a large increase in the incidence of liver disease-related deaths in HCV-seropositive patients in adjusted models (IRR, 11.71 [95% CI, 6.42-21.34]). Among 2260 patients of known HCV serostatus initiating HAART, after adjustment, there was no significant difference between HCV-seropositive and -seronegative patients with respect to virologic response (relative hazard [RH], 1.13 [95% CI, 0.84-1.51]) and immunologic response, whether measured as a > or = 50% increase (RH, 0.94 [95% CI, 0.77-1.16]) or a > or = 50 cells/microL increase (RH, 0.92 [95% CI, 0.77-1.11]) in CD4 cell count after HAART initiation. CONCLUSIONS: HCV serostatus did not affect the risk of HIV-1 disease progression, but the risk of liver disease-related deaths was markedly increased in HCV-seropositive patients. The overall virologic and immunologic responses to HAART were not affected by HCV serostatus.
Keywords
Adult, Anti-HIV Agents/therapeutic use, Antiretroviral Therapy, Highly Active, CD4 Lymphocyte Count, Cohort Studies, Disease Progression, Female, HIV Infections/complications, HIV Infections/drug therapy, HIV-1/isolation & purification, Hepatitis C/complications, Hepatitis C/immunology, Hepatitis C Antibodies/blood, Humans, Male, Middle Aged, RNA, Viral/blood, Risk Factors, Survival Analysis
Pubmed
Web of science
Open Access
Yes
Create date
19/11/2007 12:34
Last modification date
20/08/2019 13:23
Usage data